Review the literature on the economic evaluation of PCV-10, PCV-13 and PPSV-23 for providing references for decision-making and research in China. A total of 17 literatures were included, and the basic information to descriptive characteristics, methodology, modeling and the results were extracted. The 14 studies adopted Markov model, 2 studies adopted decision tree model and 1 study adopted probabilistic model. The cost including vaccine price and administration costs, direct medical expenses and indirect lost. All the 17 studies use QALY as the outcome, some studies also use LYG as the outcome. 9 of 13 studies (69.2%) involving people over the age of 50 concluded that pneumococcal vaccination was cost-effective. To provide effective references for decision-makers, China should collect the relevant epidemiological parameters, vaccine effect of pneumococcal disease in the Chinese population and carry out the economic evaluation of pneumococcal vaccination.
综合分析国内外PCV-10、PCV-13、PPSV-23疫苗经济学评价文献为我国有关决策和研究开展提供参考。本综述共纳入17项研究，对纳入研究的基本信息、模型、方法学及评价结果等信息进行整理分析。14项研究使用马尔可夫模型，2项研究使用决策树模型，1项研究使用概率模型。成本测算主要包括疫苗及接种费用、相关疾病直接医疗费用及间接损失三大类，效果的测算均使用QALY，部分研究在此基础上还计算了LYG作为效果的一部分。13项以50岁以上人群为研究的对象的研究中9项（69.2%）研究认为接种肺炎球菌疫苗是具有经济性的。我国应当收集本土人群肺炎球菌疾病相关流行病学参数及疫苗效果，开展基于我国本土数据的肺炎球菌疫苗接种经济学评价，为决策者提供相应的参考依据。.